

### LISTING OF THE CLAIMS AS AMENDED

Please amend claims 17-18, 27-28, and 31 so that they read as-follows:

17. (Currently Amended) A biological tissue comprising endothelial cells which may be induced to generate a compound which down-regulates the surface expression of a cell adhesion molecule by the cells, the compound being ~~either (a) a polynucleotide complementary in sequence to part of the gene or mRNA that encodes the cell adhesion molecule, (b) a polynucleotide comprising a ribozyme sequence that specifically targets a gene or mRNA that encodes the cell adhesion molecule, or (c) a peptide or polypeptide with specific binding affinity for the cell adhesion molecule,~~ the endothelial cells comprising a vector which encodes the peptide or polypeptide under the control of an inducible promoter.

18. (Currently Amended) A tissue according to claim 20 ~~17~~, wherein said polypeptide ~~(e)~~ is a bispecific fusion protein.

19. (Withdrawn) A polypeptide comprising a binding region capable of binding to a cell adhesion molecule and a signalling region for subcellular targeting of the polypeptide such that is not transported to the cell surface.

20. (Withdrawn) A polypeptide according to claim 22, which comprises an antibody or antibody fragment.

21. (Withdrawn) A polypeptide according to claim 23, which comprises a single chain Fv fragment.

22. (Withdrawn) A polypeptide according to claim 22, wherein the signalling region for subcellular targeting of the polypeptide comprises a localisation signal for the endoplasmic reticulum.

23. (Withdrawn) A polypeptide according to claim 25, wherein the signalling region comprises the amino acid sequence KDEL at the C terminus of the polypeptide.

24. (Withdrawn) A polypeptide according to claim 22, wherein said binding region has affinity for any one of the adhesion molecules VCAM-1, ICAM-1, LFA-1, CD2, PECAM, CD31, IAP, CD47 or integrin  $\alpha v \beta 3$ .

25. (Withdrawn) A polynucleotide encoding a polypeptide according to claim 22.

26. (Withdrawn) A vector comprising a polynucleotide according to claim 28.

27. (Currently Amended) An endothelial cell comprising a transformed with a nucleic acid that encodes a polypeptide, polynucleotide according to claim 28 or a vector according to claim 29 wherein said polypeptide comprises a binding region capable of binding to a cell adhesion molecule and a signalling region for subcellular targeting of the polypeptide such that the cell adhesion molecule is not transported to the cell surface.

28. (Currently Amended) A biological tissue comprising a cell according to claim 30 ~~27~~.

29. (Withdrawn) A non-human animal comprising biological tissue according to claim 31 and/or a cell according to claim 30.

30. (Withdrawn) An animal according to claim 32, wherein said animal is a transgenic pig or sheep.

31. (Currently Amended) A method of ~~rendering a~~ prolonging survival of a tissue or organ graft suitable for transplantation, comprising expressing a polypeptide ~~according~~

~~to claim 22~~ in endothelial cells in said tissue or organ, ~~thereby down-regulating the~~ so that surface expression of a cell adhesion molecule is down regulated,

wherein said polypeptide comprises a binding region capable of binding to a cell adhesion molecule and a signaling region for subcellular targeting of the polypeptide such that the cell adhesion molecule is not transported to the cell surface, and wherein down regulation of the surface expression of said cell adhesion molecule prolongs the survival of a tissue or organ graft.

32. (Withdrawn) A method of transplantation, comprising transplanting biological tissue according to claim 31 from a donor animal into a recipient animal.

\* \* \* \* \*